Company Overview of Moderna Therapeutics, Inc.
Moderna Therapeutics, Inc. develops messenger RNA therapeutics. The company provides in vivo drug modality that produces human proteins or antibodies inside patient cells. It also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. The company focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology. Moderna Therapeutics, Inc. has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals, Inc.; and strategic collaborations with Karolinska Institutet, Institut Pasteur, and Karolinska University Hospital. The company was incorporated in 2009 and is based...
200 Tech Square
Cambridge, MA 02139
Founded in 2009
Key Executives for Moderna Therapeutics, Inc.
Founding Chief Executive Officer, President and Director
Co-Founder, Chairman and Member of Technology Advisory Board
President of Research and Development
Senior Vice President of Technology Strategy
Compensation as of Fiscal Year 2014.
Moderna Therapeutics, Inc. Key Developments
Moderna Therapeutics Enters into Research Collaboration with Institut Pasteur
Feb 5 15
Moderna Therapeutics has entered into a long-term strategic research collaboration with Institut Pasteur. The contract has been signed to discover and develop drugs and vaccines using its mRNA Therapeutics platform. It will be managed by its venture company, Valera, which is focused on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases. Under the deal, Valera will sponsor programmes of preclinical and clinical research at the Institut Pasteur, aimed at discovering and developing new approaches to combat known and emerging viral and bacterial diseases.
Moderna Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:50 PM
Jan 30 15
Moderna Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:50 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Lorence H. Kim, Chief Financial Officer, Stephane Bancel, CEO.
Moderna Therapeutics Announces a License and Collaboration Agreement with Merck
Jan 13 15
Moderna Therapeutics announced a license and collaboration agreement with Merck. Moderna is a pioneer in the development of mRNA Therapeutics across a range of therapeutic applications. Moderna's work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. The vaccines work of Valera builds on a body of preclinical research at Moderna showing the ability of modified mRNA to express viral antigens in vivo and to induce robust immune responses. Valera's therapeutic passive immunity programs will expand on Moderna's research using mRNA to express antibodies that bind to viral and other targets. The robust data in these programs across a range of preclinical infectious disease models, together with the inherent, rapid turn-around time in creating novel mRNA constructs, provide Valera with a potentially powerful and versatile new platform for the creation of a broad array of vaccines and passive immunity therapies. The three-year research collaboration (with the possibility of a one-year extension) is focused on the development of new mRNA-based treatments and vaccines against four undisclosed viruses. Under the terms of the agreement, Merck will make an upfront cash payment to Moderna of $50 million to give Merck the ability to utilize the granted licenses to commercialize five product candidates, and will make a $50 million equity investment in Moderna.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 19, 2014